medigraphic.com

2014, Número 2

<< Anterior Siguiente >>

Rev Med MD 2014; 5.6 (2)


Alteraciones del metabolismo mineral y óseo asociadas a la enfermedad renal crónica

Trujillo-Cuellar H , Sierra-Lara Martínez JD , Osorno-Solís L

Idioma: Español
Referencias bibliográficas: 68
Paginas: 151-160
Archivo PDF: 212.06 Kb.


RESUMEN

Las alteraciones del metabolismo mineral y óseo asociadas a la enfermedad renal crónica representan un importante conjunto de anormalidades que se presentan casi universalmente en este grupo de pacientes. Se han asociado a un aumento en la morbilidad, mortalidad y deterioro de la calidad de vida en los enfermos renales crónicos. La mayor parte de los estudios que existen al respecto son observacionales y han reportado resultados contradictorios, por lo que permanece como un campo abierto a la investigación. Se realiza una revisión de la literatura, con el objetivo de presentar la información más actual y relevante sobre el tema.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1.Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidne y Int 2009; 76 (Suppl 113):S1–S130.

  2. 2.Tonelli M, Pannu N, Manns B. Oral Phosphate Binders in Patients with Kidney Failure. N Engl J Med 2010;362:1312-24.

  3. 3.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42 (Suppl 3):S1-S201.

  4. 4.Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008;74:148-57.

  5. 5.Sherman RA. Dietary phosphate restriction and protein intake in dialysis patients: a misdirected focus. Semin Dial 2007;20:16-8.

  6. 6.Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520–528.

  7. Dhingra R, Sullivan LM, Fox CS et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879–885.

  8. 8.Tonelli M, Sacks F, Pfeffer M et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627–2633.

  9. 9.Menon V, Greene T, Pereira AA et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005;46:455–463.

  10. 10.Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519–530.

  11. 11.Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidit y in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208–2218.

  12. 12.Noordzij M, Korevaar JC, Boeschoten EW et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005;46:925–932.

  13. 13.Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179–1187.

  14. 14.Kimata N, Albert JM, Akiba T et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int 2007;11:340–348.

  15. 15.Evenepoel P, Rodriguez M Ketteler M. Laboratory Abnormalities in CKD-MBD: Markers, Predictors, or Mediators of Disease? Semin Nephrol 2014; 34:151- 163

  16. 16.Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31–38.

  17. 17.Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implicatios for establishing a new effective dietar y intake recommendation for vitamin D. J Nutr 2005; 135: 317–322.

  18. 18.Hollis BW. Assessment of vitamin D status and definition of a normal circulating range of 25- hydroxyvitamin D. Curr Opin Endocrinol Diabetes Obes 2008; 15: 489–494. 19.Ketteler M, Brandenburg V, Jahnen-Dechent W et al. Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse. Nephrol Dial Transplant 2005; 20: 673–677.

  19. 20.O’Neill WC. The fallacy of the calcium-phosphorus product. Kidney Int 2007; 72: 792–796. 21.Dolores Prados-Garrido M, Bover J, Gonzalez Alvarez M, et al.Guia de practica clínica de la Sociedad Española de Diálisis y Trasplante de las alteraciones del metabolismo mineral y oseo de la enfermedad renal cronica (CKD-MBD). Dial Traspl 2011;32(3):108—118.

  20. 21.Dolores Prados-Garrido M, Bover J, Gonzalez Alvarez M, et al.Guia de practica clínica de la Sociedad Española de Diálisis y Trasplante de las alteraciones del metabolismo mineral y oseo de la enfermedad renal cronica (CKD-MBD). Dial Traspl 2011;32(3):108—118.

  21. Bakkaloglu SA, Wesseling-Perry K, Pereira RC, et al. Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol 2010; 5:1860.

  22. 23.Araujo SM, Ambrosoni P, Lobao RR et al. The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int 2003; 63(Suppl 85): S54–56

  23. Kanis JA, Johnell O, Oden A et al. FRAX and the assessment of fracture pro- bability in men and women from the UK. Osteoporos Int 2008; 19: 385–397.

  24. 25.Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 2007; 49: 674–681.

  25. 26.Coen G, Ballanti P, Bonucci E et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 2002; 91: 103–111.

  26. Hutchison AJ, Whitehouse RW, Boulton HF et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993; 44: 1071–1077 28.Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141–2156.

  27. 28.Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141–2156.

  28. Ivaska KK, Gerdhem P, Akesson K et al. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 2007; 22: 1155–1164

  29. 30.Garnero P, Sornay-Rendu E, Claustrat B et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526–1536.

  30. 31.Ketteler M, Schlieper G, Floege J. Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 2006; 47: 1027–1034.

  31. 32.Oei HH, Vliegenthart R, Deckers JW et al. The association of Rose questionnaire angina pectoris and coronary calcification in a general population: the Rotterdam Coronary Calcification Study. Ann Epidemiol 2004; 14: 431–436

  32. 33.Sigrist M, Bungay P, Taal MW et al. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant 2006; 21: 707–714.

  33. 34.Tatler GL, Baillod RA, Varghese Z et al. Evolution of bone disease over 10 years in 135 patients with terminal renal failure. BMJ 1973; 4: 315–319.

  34. 35.Massy ZA, Drüeke TB. Vascular calcification. Curr Opin Nephrol Hypertens 2013; 22:405.Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438–441.

  35. 36.Bellasi A, Ferramosca E, Muntner P et al. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int 2006; 70: 1623–1628.

  36. 37.Vliegenthart R, Oudkerk M, Song B et al. Coronary calcification detected by electron-beam computed tomography and myocardial infarction. The Rotterdam Coronary Calcification Study. Eur Heart J 2002; 23: 1596–1603. 255.

  37. 38.Goldfarb S, Martin KJ. Disorders of Divalent Ions, Renal Bone Disease, and Nephrolithiasis. NephSAP 2012;11(4):231-302.

  38. Cozzolino M, Mazzaferro S, Brandenburg V: The treatment of hyperphosphataemia in CKD: Calciumbased or calcium-free phosphate binders? Nephrol Dial Transplant 2011;26:402–407.

  39. 40.Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 1996;45:111-9.

  40. 41.Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54:619-37.

  41. 42.Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7. 43.Tonelli M, Wiebe N, Culleton B et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007;22:2856-66.

  42. Jamal SA, Fitchett D, Lok CE, Mendelssohn DC, Tsuyuki RT. The effects of calcium-based versus noncalcium- based phosphate binders on mortality among patients with chronic kidney disease: a metaanalysis. Nephrol Dial Transplant 2009;24:3168-74.

  43. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006;65:191-202.

  44. 46.Tzanakis IP, Papadaki AN, Wei M et al. Magnesium carbonate for phosphate control in patients on hemodialysis: a randomized controlled trial. Int Urol Nephrol 2008;40:193-201.

  45. 47.Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 1996;49:163-7.

  46. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ Jr et al. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am J Kidney Dis 2011;58:536–543.

  47. 49.Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies. Am J Kidney Dis 2011 58: 374–382.

  48. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T et al. Cholecalciferol supplementation in hemodialysis patients: Effect son mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010;5: 905–911.

  49. 51.Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD et al. Oral cholecalciferol decreases albuminuria and urinary TGF-b1 in patients with type 2 diabetic nephropathy on established renin-angiotensin- aldosterone system inhibition. Kidney Int 2011;80:851–860.

  50. 52.Shireman TI, Almehmi A, Wetmore JB, Lu J, Pregenzer M, Quarles LD. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis 2010;56:1108–1116.

  51. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K et al. ADVANCE Study Group: The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011;26:1327–1339.

  52. 54.Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG et al. EVOLVE Trial Investigators: Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. N Engl J Med 2012;367:2482-94.

  53. 55.Sigrist M, McIntyre CW. Calcium exposure and removal in chronic hemodialysis patients. J Ren Nutr 2006;16:41–46.

  54. 56.Mc Intyre CW. Calcium balance during hemodialysis. Semin Dial 2008;21:38–42.

  55. 57.Culleton BF, Walsh M, Klarenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298:1291–1299.

  56. 58.Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67:760–771.

  57. 59.Jofre R, Lopez Gomez JM, Menarguez J et al. Parathyroidectomy: whom and when? Kidney Int 2003; 63: S97–100.

  58. 60.Neonakis E, Wheeler MH, Krishnan H et al. Results of surgical treatment of renal hyperparathyroidism. Arch Surg 1995;130:643–648.

  59. 61.Gasparri G, Camandona M, Abbona GC et al. Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies. Ann Sur 2001;233:65–69.

  60. 62.Gagne ER, Urena P, Leite-Silva S et al. Short and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992;3:1008–1017.

  61. 63.Kestenbaum B, Andress DL, Schwartz SM et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004;66:2010–2016.

  62. 64.Trombetti A, Stoermann C, Robert JH et al. Survival after parathyroidectomy in patients with end-stage renal disease and severe hyperparathyroidism. World J Sur 2007;31:1014–1021.

  63. 65.Lu KC, Yeung LK, Lin SH et al. Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients withs econdaryh y perpara thyroidism. Am J Kidney Dis 2003;42:1221–1227.

  64. 66.Amerling R, et al. Bisphosphonate use in chronic kidney disease associated with adynamic bone disease. Abstract from the ISN Nexus Symposium on the Bone and the Kidney, 12–15 October 2006, Copenhagen, Denmark. International Society of Nephrology (ISN): Brussels, Belgium, 2006, p 33.

  65. 67.Hernandez E, et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 2003;63:2269–2274.

  66. 68.Hamdy NA, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995;310:358–363.

  67. 69.Baker LR, et al. Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 1986;26:185–191.

  68. 70.Cozzolino M, et al. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol Dial Transplant 2014;29:1815-182




2020     |     www.medigraphic.com